Alnylam Pharmaceuticals (ALNY) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 May, 2026Opening remarks and agenda
Meeting called to order virtually, with all board members and senior management present.
Introduction of directors, senior management, and independent auditors.
Stockholders welcomed and thanked for participation and voting.
Board and executive committee updates
Three Class I directors nominated for election to serve three-year terms.
All board members and key executives introduced, including CEO and CFO.
Shareholder proposals
Proposals included election of directors, advisory vote on executive compensation, and ratification of auditors.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alnylam Pharmaceuticals
- Strong AMVUTTRA growth, pipeline expansion, and robust cash position drive future outlook.ALNY
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenues rose 121% year-over-year to $1.04B, led by AMVUTTRA and TTR growth.ALNY
Q1 202630 Apr 2026 - 2025 revenues rose 81% to $2.99B, with profitability and strong 2026 growth guidance.ALNY
Q4 202520 Apr 2026 - AMVUTTRA accelerates growth and leadership in ATTR-CM with strong clinical, market, and AI-driven momentum.ALNY
Status update13 Apr 2026 - Virtual meeting to vote on directors, pay, and auditor amid record growth and ESG advances.ALNY
Proxy filing6 Apr 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.ALNY
Proxy filing6 Apr 2026 - Strong growth, innovative pipeline, and disciplined R&D investment drive long-term expansion.ALNY
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Vutrisiran met all endpoints in Phase 3 ATTR-CM study, reducing mortality and CV events.ALNY
Study Result3 Feb 2026 - Q2 2024 revenues up 107% to $660M, led by TTR growth and HELIOS-B results.ALNY
Q2 20242 Feb 2026